Advertisement

Ads Placeholder
Loading...

BB Biotech AG

BBZA.DEXETRA
Healthcare
Biotechnology
48.35
0.15(0.31%)
German Market is Open • 15:02

BB Biotech AG (BBZA.DE) Stock Competitors & Peer Comparison

See (BBZA.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BBZA.DE€48.05-0.93%2.7B-5.60-€8.60+5.09%
NOV.DE€31.06-2.37%139.5B10.19€3.08+4.06%
VX1.DE€391.20+1.26%98.9B29.31€13.28N/A
DUL.DE€282.50-1.38%37.8B140.97€2.02N/A
22UA.F€76.10+0.26%19.4B-16.39-€4.70N/A
0QF.F€42.43+1.52%17.1B-6.84-€6.32N/A
BM8.DE€61.96-1.71%11.8B88.51€0.70N/A
EX9.DE€32.28+1.22%9.2B35.47€0.91N/A
MOR.DE€67.25-0.66%2.5B-12.16-€5.53N/A
BIO3.DE€32.40+1.25%1.6B-51.43-€0.63+0.12%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BBZA.DE vs NOV.DE Comparison April 2026

BBZA.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BBZA.DE stands at 2.7B. In comparison, NOV.DE has a market cap of 139.5B. Regarding current trading prices, BBZA.DE is priced at €48.05, while NOV.DE trades at €31.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BBZA.DE currently has a P/E ratio of -5.60, whereas NOV.DE's P/E ratio is 10.19. In terms of profitability, BBZA.DE's ROE is -0.13%, compared to NOV.DE's ROE of +0.61%. Regarding short-term risk, BBZA.DE is more volatile compared to NOV.DE. This indicates potentially higher risk in terms of short-term price fluctuations for BBZA.DE.Check NOV.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions